Status:
UNKNOWN
Intensity-Modulated Radiation Therapy in Treating Patients With Prostate Cancer
Lead Sponsor:
Royal Marsden NHS Foundation Trust
Conditions:
Prostate Cancer
Eligibility:
MALE
Phase:
PHASE1
Brief Summary
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. PURPOSE: This phase I trial is ...
Detailed Description
OBJECTIVES: * To test the feasibility of delivering hypofractionated intensity-modulated radiotherapy to the prostate and pelvic nodes of patients with prostate cancer. * To determine the optimal dos...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of prostate cancer meeting 1 of the following criteria:
- Stage T3b/T4 disease or radiological or pathological pelvic nodal metastases
- Localized disease (stage pT2-T4) with \> 30% estimated risk of pelvic nodal metastases
- High-risk (Gleason score ≥ 8 or ≥ 2 risk factors) or very high-risk disease according to the National Collaborative Cancer Network (NCCN)
- Has undergone prostatectomy AND has stage T2-T3a, N0 disease with extensive high-risk disease (Gleason score ≥ 8) or seminal vesicle or lymph node involvement
- Candidate for radical radiotherapy
- PATIENT CHARACTERISTICS:
- No inflammatory bowel disease or other small bowel disease
- PRIOR CONCURRENT THERAPY:
- No prior pelvic radiotherapy or surgery (excluding prostatectomy)
Exclusion
Key Trial Info
Start Date :
March 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
198 Patients enrolled
Trial Details
Trial ID
NCT00946543
Start Date
March 1 2000
Last Update
August 26 2013
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Cancer Research - Chelsea
London, England, United Kingdom, SW3 6JB
2
Institute of Cancer Research - Sutton
Sutton, England, United Kingdom, SM2 5NG
3
Royal Marsden - Surrey
Sutton, England, United Kingdom, SM2 5PT